Selank: interpreting cognitive and mood claims
A cautious guide to regional approvals, study quality, and claims made in the United States.
Educational information only — not medical advice. This material cannot diagnose a condition, recommend treatment, or replace care from a qualified clinician who knows your history. The Peptide Center uses an evidence-first editorial process that prioritizes primary regulatory sources, trial registries, and peer-reviewed research; uncertainty and evidence limits should be part of every health claim.
Selank has no FDA-approved therapeutic use in the United States. Regulatory status in another country, a proposed mechanism, or an early study does not establish FDA approval or prove a clinical benefit for a product sold in the United States.
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
BDNF
An evidence-first reference for reading claims and source material about BDNF.
Open resourcePeptide briefDihexa
An evidence-first reference for reading claims and source material about Dihexa.
Open resourcePeptide briefDihexa / Tesofensine / BPC-157
An evidence-first reference for reading claims and source material about Dihexa / Tesofensine / BPC-157.
Open resourcePeptide briefDSIP
An evidence-first reference for reading claims and source material about DSIP.
Open resourcePeptide briefMethylene Blue / Methylliberine
An evidence-first reference for reading claims and source material about Methylene Blue / Methylliberine.
Open resourcePeptide briefOxytocin
An evidence-first reference for reading claims and source material about Oxytocin.
Open resourceArticleHow to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resource